ATE496066T1 - Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta - Google Patents
Verfahren zur prävention von tumorrezidiven durch blockade von tgf-betaInfo
- Publication number
- ATE496066T1 ATE496066T1 AT03779310T AT03779310T ATE496066T1 AT E496066 T1 ATE496066 T1 AT E496066T1 AT 03779310 T AT03779310 T AT 03779310T AT 03779310 T AT03779310 T AT 03779310T AT E496066 T1 ATE496066 T1 AT E496066T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- tgf
- agent
- tumor
- recurrence
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 5
- 230000000903 blocking effect Effects 0.000 title 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 4
- 230000019491 signal transduction Effects 0.000 abstract 3
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 108091005735 TGF-beta receptors Proteins 0.000 abstract 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42128602P | 2002-10-25 | 2002-10-25 | |
| PCT/US2003/034023 WO2004037209A2 (en) | 2002-10-25 | 2003-10-24 | METHODS TO PREVENT TUMOR RECURRENCE BY BLOCKADE OF TGF-β |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496066T1 true ATE496066T1 (de) | 2011-02-15 |
Family
ID=32176694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03779310T ATE496066T1 (de) | 2002-10-25 | 2003-10-24 | Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060057145A1 (de) |
| EP (1) | EP1556071B1 (de) |
| JP (1) | JP4989850B2 (de) |
| AT (1) | ATE496066T1 (de) |
| AU (1) | AU2003284994B2 (de) |
| CA (1) | CA2502663C (de) |
| DE (1) | DE60335817D1 (de) |
| WO (1) | WO2004037209A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006089251A2 (en) * | 2005-02-17 | 2006-08-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SYNERGISTIC EFFECT OF TGF-β BLOCKADE AND IMMUNOGENIC AGENTS ON TUMORS |
| EP2058388A1 (de) * | 2007-10-05 | 2009-05-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nicht-konventionelle NKT-Zellen zur Verwendung in der Krebstherapie |
| CN102216448A (zh) * | 2008-11-13 | 2011-10-12 | 分子医学研究院 | Foxp3+天然杀伤t细胞及免疫相关疾病的治疗 |
| JP2012524818A (ja) * | 2009-04-24 | 2012-10-18 | バンダービルト ユニバーシティ | 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法 |
| WO2016001276A1 (en) * | 2014-07-02 | 2016-01-07 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods for diagnosing and treating cd1d restricted gamma/delta t cell lymphomas |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189790B (en) * | 1985-10-03 | 1990-03-21 | Sumitomo Rubber Ind | Ionomer resin |
| US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| ZA912490B (en) * | 1990-04-19 | 1992-12-30 | Res Dev Foundation | Antibody conjugates for treatment of neoplastic disease |
| US6297041B1 (en) * | 1992-03-11 | 2001-10-02 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| US5470952A (en) * | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
| DE19613691A1 (de) * | 1996-04-05 | 1997-10-09 | Boehringer Ingelheim Int | Arzneimittel für die Behandlung von Tumorerkrankungen |
| US6046165A (en) * | 1997-06-23 | 2000-04-04 | Ophidian Pharmaceuticals, Inc. | Compositions and methods for identifying and testing TGF-β pathway agonists and antagonists |
| JP4027485B2 (ja) * | 1998-01-14 | 2007-12-26 | 中外製薬株式会社 | 医薬品のスクリーニング方法ならびに医薬品の分子設計方法 |
| US6410043B1 (en) * | 1998-05-07 | 2002-06-25 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| US20040197333A1 (en) * | 2000-02-10 | 2004-10-07 | Cornell Research Foundation, Inc. | Use of TGF-beta antagonists to inhibit tumor cell formation or progression |
| US20030125251A1 (en) * | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
-
2003
- 2003-10-24 AT AT03779310T patent/ATE496066T1/de not_active IP Right Cessation
- 2003-10-24 EP EP03779310A patent/EP1556071B1/de not_active Expired - Lifetime
- 2003-10-24 DE DE60335817T patent/DE60335817D1/de not_active Expired - Lifetime
- 2003-10-24 US US10/532,374 patent/US20060057145A1/en not_active Abandoned
- 2003-10-24 CA CA2502663A patent/CA2502663C/en not_active Expired - Fee Related
- 2003-10-24 AU AU2003284994A patent/AU2003284994B2/en not_active Ceased
- 2003-10-24 JP JP2004547201A patent/JP4989850B2/ja not_active Expired - Fee Related
- 2003-10-24 WO PCT/US2003/034023 patent/WO2004037209A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP1556071B1 (de) | 2011-01-19 |
| AU2003284994B2 (en) | 2009-11-12 |
| US20060057145A1 (en) | 2006-03-16 |
| CA2502663C (en) | 2015-10-06 |
| EP1556071A2 (de) | 2005-07-27 |
| DE60335817D1 (de) | 2011-03-03 |
| JP4989850B2 (ja) | 2012-08-01 |
| WO2004037209A3 (en) | 2004-11-25 |
| AU2003284994A1 (en) | 2004-05-13 |
| WO2004037209A2 (en) | 2004-05-06 |
| EP1556071A4 (de) | 2009-07-15 |
| JP2006503899A (ja) | 2006-02-02 |
| CA2502663A1 (en) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE446751T1 (de) | Verwendung von methylnaltrexon zur behandlung von immunsuppression | |
| ATE250932T1 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
| EA200401284A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf | |
| EA200870029A1 (ru) | Способ применения антагонистов il-6 с ингибиторами протеасом | |
| CY1108092T1 (el) | Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora | |
| EA200600689A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов raf киназы | |
| DE60039783D1 (de) | Lfa-1 antagonisten und tnf-alpha antagonisten zur | |
| ATE334985T1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
| BRPI0512500A (pt) | tratamento ou condições envolvendo desmielinação | |
| CY1115745T1 (el) | Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου | |
| UY27729A1 (es) | Inhibidores de quinasas. | |
| TW200611911A (en) | Antibodies to erythropoietin receptor and uses thereof | |
| DE60319364D1 (de) | Substituierte pyrroline als kinase inhibitoren | |
| DE60323749D1 (de) | Substituierte pyrroline als kinase inhibitoren | |
| HK1080092A1 (en) | Vegf antagonists for the treatment of diabetes | |
| MEP48108A (en) | 4-tetrazolyl-4phenylpiperidine derivatives for treating pain | |
| EA200801853A1 (ru) | Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток | |
| ATE407698T1 (de) | Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung | |
| CY1109031T1 (el) | Τριαζασπιρο ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου | |
| DE60108489D1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
| ATE481101T1 (de) | Verfahren zur behandlung von angstzuständen | |
| ATE496066T1 (de) | Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta | |
| WO2004100885A3 (en) | Compositions and methods for treating cancer | |
| DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
| HK1071079A1 (en) | Use of soluble fgl2 as an immunosuppressant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |